CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$53.55 USD
+0.26 (0.49%)
Updated May 9, 2024 04:00 PM ET
After-Market: $53.52 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
CRISPR Therapeutics AG (CRSP) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$88.05 | $199.00 | $30.00 | 65.23% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for CRISPR Therapeutics AG comes to $88.05. The forecasts range from a low of $30.00 to a high of $199.00. The average price target represents an increase of 65.23% from the last closing price of $53.29.
Analyst Price Targets (22)
Broker Rating
CRISPR Therapeutics AG currently has an average brokerage recommendation (ABR) of 2.17 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 27 brokerage firms. The current ABR compares to an ABR of 2.17 a month ago based on 27 recommendations.
Of the 27 recommendations deriving the current ABR, 13 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 48.15% and 3.7% of all recommendations. A month ago, Strong Buy made up 48.15%, while Buy represented 3.7%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 13 | 13 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 10 | 10 | 10 | 10 | 9 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.17 | 2.17 | 2.17 | 2.17 | 2.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/6/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
4/12/2024 | SVB Securities | Mani Foroohar | Strong Buy | Strong Buy |
4/11/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
3/5/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
2/22/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
2/1/2024 | Robert W. Baird & Co. | Jack K Allen | Hold | Hold |
1/29/2024 | Evercore Partners | Liisa A Bayko | Hold | Hold |
12/8/2023 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
12/5/2023 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
11/7/2023 | William Blair | Sami Corwin | Strong Buy | Strong Buy |
11/7/2023 | Not Identified | Not Identified | Strong Sell | Strong Sell |
11/6/2023 | Brookline Capital Markets | Leah R Cann | Strong Buy | Strong Buy |
10/18/2023 | Cantor Fitzgerald & Co | Eric Schmidt | Hold | Hold |
9/1/2023 | BMO Capital Markets | Kostas Biliouris | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.17 |
ABR (Last week) | 2.17 |
# of Recs in ABR | 27 |
Average Target Price | $88.05 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | -1.67 |